Sonomind SAS raised €20 million (US$23 million) in a Series A round to advance its ultrasound-based neuromodulation device for treatment-resistant depression. The company will use the funds to run clinical trials of the non-invasive system designed to deliver targeted acoustic energy to deep brain regions. Sonomind’s platform relies on a custom-made acoustic lens intended to focus the ultrasound to specific neural targets. The company positioned its approach as an alternative to invasive neuromodulation methods, aiming to reach patients who have limited response to pharmacotherapy. The financing comes as investors continue to fund neuromodulation technologies that can demonstrate mechanistic targeting and differentiated clinical endpoints in psychiatric indications. For developers, the key near-term catalyst is clinical trial execution—safety, tolerability, and symptom response in treatment-resistant populations will determine how ultrasound neuromodulation competes with other device and drug approaches.